Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05280366 · ClinicalTrials.gov registry record · NA

STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma

A NA study of Open Angle Glaucoma, sponsored by New World Medical.

Active
Registry status
NA
Development phase
150
Enrollment target
20
Study locations

NCT05280366 is a NA study of Open Angle Glaucoma that is active but no longer recruiting, run by New World Medical. The registered enrollment target is 150 participants, below the 329-participant average among 28 other Open Angle Glaucoma trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05280366, a NA study of Open Angle Glaucoma, is active but no longer recruiting, sponsored by New World Medical.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
20
Study locations

Study Summary

A study of the Streamline Surgical System versus competitor

Conditions Studied

Interventions

  • DEVICE Streamline Surgical System
  • DEVICE iStent Inject W

Study Locations (20)

Texas

  • Ophthalmology Associates - Fort Worth
  • Berkely Eye Center - Houston
  • R & R Eye Research - San Antonio

California

  • Visionary Research Institute - Newport Beach
  • Wolstan and Goldberg Eye Associates - Torrance

New Jersey

  • Eye Associates of North New Jersey - Dover
  • Eye Associates Surgical Center - Vineland

Other

  • Clinica 20/20 - San José
  • Clinica Laser y Ultrasonido Ocular - Puebla City

Arkansas

  • Vold Vision - Fayetteville

Colorado

  • University of Colorado - Aurora

Florida

  • Ocala Eye - Ocala

Georgia

  • Georgia Eye Partners - Atlanta

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2022-02-09
Est. Completion 2026-06-30
Phase NA

Sponsor

New World Medical

2 total trials

What the Registry Record Tells You About NCT05280366

The ClinicalTrials.gov registry entry for NCT05280366 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 329-participant average among 28 other Open Angle Glaucoma trials with a reported enrollment target (54% lower). The listed sponsor is New World Medical, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Open Angle Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Streamline Surgical System is the first listed.

NCT05280366 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Texas, California, New Jersey.

Frequently Asked Questions

What is clinical trial NCT05280366 about?

NCT05280366 is a clinical study titled "STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma". A study of the Streamline Surgical System versus competitor

What is the current status of trial NCT05280366?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2022-02-09. Estimated completion is 2026-06-30.

What conditions does trial NCT05280366 study?

This clinical trial studies the following conditions: Open Angle Glaucoma.

What interventions are being tested in trial NCT05280366?

The interventions under investigation include: Streamline Surgical System (DEVICE), iStent Inject W (DEVICE).

Who is sponsoring clinical trial NCT05280366?

This trial is sponsored by New World Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05280366 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Open Angle Glaucoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.